Valion Bio, Inc. stock traded on the Nasdaq exchange on June 24, 2026, as the company also sought clearance for its flagship product from the FDA.
7 reports, 3 independent
Updated Sep 22
Gone quiet
- Reports
- 7
- Developments
- 2
- Repetition
- 71%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Valion Bio, Inc. stock traded on the Nasdaq exchange on June 24, 2026, as the company also sought clearance for its flagship product from the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Valion Bio, Inc. received Fast Track designation from the FDA and confirmed Lisa Wolf as CFO.1 source
Valion Bio, Inc. stock traded on Nasdaq while seeking FDA clearance for its flagship product.1 source
Keep exploring
The entities involved
Related events
- GeneDx Holdings Corp. securities began trading on the Nasdaq exchange on June 1, 2026.
- Argenex SE and Capricor Therapeutics were listed on the Nasdaq stock exchange and are competing in the biotech sector.
- Valion Bio, Inc. is seeking a reverse stock split to maintain its listing on the Nasdaq stock exchange.
- Regencell Bioscience Holdings Limited began trading on the electronic stock exchange on June 1, 2026, while facing a lawsuit invoking federal securities laws.
- Generate Biomedicines Inc listed its shares on the Nasdaq stock exchange on August 25, 2026.